Chemomab Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

──Positive Phase 2 Results Demonstrating Safety and Antifibrotic, Anti-inflammatory, and Anticholestatic Activity in Multiple Components of Primary Sclerosing Cholangitis (PSC)──

──Establishes clinical proof of concept for the disease-modifying potential of CM-101 and provides basis for progression to PSC Phase 3 Pivotal Trial──